All In MedTech

FDA Clearance Tracker · P170013-S009

Low-Profile Visualized Intraluminal Support (LVIS) and LVIS Jr. X

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 28, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 28, 2022

Approved

Time to decision

18 days

Received Jun 10, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P170013-S009
Device name
Low-Profile Visualized Intraluminal Support (LVIS) and LVIS Jr. X
Applicant location
Aliso Viejo, CA
Received
Jun 10, 2022
Decided
Jun 28, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P170013

Device type

Device class
Class III

Every decision under product code QCA

FDA's approval statement

As written in FDA's record.

Approval to place the post-approval study titled LVIS X PAS on hold, because the sponsor does not intend to market the LVIS X and LVIS Jr. X devices in the United States at this time.

Source documents

Other decisions for MicroVention, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.